Steroid Use Side Effects

Systemic Effects

The American Academy of Dermatology notes that hyperglycemia and worsening of diabetes are common, particularly with prednisone, requiring monitoring of blood glucose levels 1
Osteoporosis and increased fracture risk are significant concerns with long-term use 1
Mood disturbances ranging from euphoria and hypomania to depression occur, with sleep disturbances occurring in >30% of patients taking corticosteroids 2
Insomnia, restlessness, and nervousness are common neuropsychiatric effects 1, 2
Cataracts, including posterior subcapsular cataracts, and increased intraocular pressure and glaucoma can occur with prolonged use 1

Topical Steroid Side Effects

The American Academy of Dermatology reports that skin atrophy, telangiectasia, striae, purpura, contact dermatitis, and rosacea can occur with topical steroid use 3
Hypothalamic-pituitary-adrenal axis suppression may occur with medium- and high-potency topical steroids, with increased risk in children due to higher skin surface/body mass ratio 3
Growth retardation is a potential concern in pediatric patients using topical corticosteroids long-term 3

Risk Factors and Prevention

Higher doses and longer duration of treatment increase the risk of adverse effects 1
Use in steroid-sensitive areas increases the risk of local side effects 3
The American Academy of Dermatology recommends using the lowest effective dose for the shortest duration possible, with regular monitoring of blood pressure and blood glucose 1, 2
Calcium and vitamin D supplementation can help prevent osteoporosis, and bone mineral density monitoring with DEXA scans is recommended for long-term users 1
Regular skin checks and ophthalmologic evaluation are essential for patients on long-term therapy 1, 3

Short-Term Side Effects of Prednisone

Common Short-Term Side Effects

Weight gain and fluid retention are among the most common side effects, often occurring within the first few weeks of therapy, as reported by the Journal of Hepatology and Arthritis care & research 4, 5
Increased appetite leading to weight gain is a common side effect, according to Arthritis care & research 5
Gastric irritation and increased risk of peptic ulcer formation can occur, as noted by Blood advances 6
Facial rounding (moon face) can begin to develop even during short-term use, as reported by the Journal of Hepatology 4
Hypertension can develop or worsen quickly, as noted by Blood advances 6

Risk Factors for Side Effects

Duration of treatment longer than 6 weeks significantly increases risk of adverse effects, as reported by Blood advances and Journal of Hepatology 6, 7
Children are at higher risk for growth suppression, according to Hepatology 8

Monitoring Recommendations

Regular monitoring of blood pressure and blood glucose is recommended, even during short courses, as noted by Blood advances 6
Weight monitoring to detect rapid fluid retention is recommended, according to Arthritis care & research 5

Important Considerations

The American Society of Hematology strongly recommends against prolonged courses (>6 weeks) of prednisone due to increased risk of side effects, as reported by Blood advances 6, 9
Most side effects are dose-dependent, with doses >20 mg/day for more than 18 months leading to severe adverse effects in about 15% of patients, as reported by the Journal of Hepatology 4, 7

Common Pitfalls to Avoid

Underestimating the impact of sleep disturbances and mood changes on quality of life can be a pitfall, as noted by Blood advances 6

Risks and Management Strategies for Long-Term Corticosteroid Use

Major Risks of Long-Term Steroid Use

Avascular necrosis of joints, particularly the femoral head, can occur even at moderate doses, affecting patients on long-term corticosteroid therapy 10
Dyslipidemia can occur with long-term use, increasing the risk of cardiovascular disease in patients taking corticosteroids 10
Increased risk of both opportunistic and non-opportunistic infections, including pneumonia, skin infections, and sepsis, is a significant concern for patients on long-term corticosteroid therapy 10

Management Strategies

Infection Prevention

Consider Pneumocystis jirovecii pneumonia prophylaxis for patients taking ≥20 mg prednisone for ≥4 weeks to prevent opportunistic infections 10
Update all vaccines before starting immunosuppressive therapy to reduce the risk of vaccine-preventable diseases 10
Avoid live vaccines in patients already taking immunosuppressants to prevent vaccine-related complications 10

Metabolic Monitoring

Consider lipid profile monitoring to assess the risk of dyslipidemia and cardiovascular disease in patients on long-term corticosteroid therapy 10

Minimizing Side Effects

Consider alternate-day therapy when appropriate to reduce adrenal suppression and minimize side effects, as recommended by the American Academy of Allergy, Asthma, and Immunology 11
Consider steroid-sparing agents when long-term therapy is anticipated to reduce the risk of corticosteroid-related complications, as suggested by the American Gastroenterological Association 12

Special Considerations

Patient Education

Educate patients about the signs of infection and when to seek medical attention to ensure prompt treatment and prevent complications 10

High-Risk Populations

Elderly patients require more careful monitoring and often lower doses due to increased risk of complications, as recommended by the American Geriatrics Society 10
Patients with diabetes, chronic liver disease, or chronic kidney disease have increased risk of complications and require close monitoring, as suggested by the American Diabetes Association and other specialty societies 10

Long-Term Complications of Prednisone Therapy

Common Systemic Complications

Osteoporosis and increased fracture risk are among the most serious complications, particularly in postmenopausal women, with vertebral compression fractures occurring in up to 27% of patients requiring treatment withdrawal 13
Aseptic necrosis of femoral and humeral heads can develop even at moderate doses, and myopathy affecting diaphragmatic and intercostal muscles may complicate assessment of therapeutic efficacy 14
Redistribution of body fat with truncal obesity, moon facies, and buffalo hump occurs in 80% of patients after two years of therapy 13
Posterior subcapsular cataracts develop with prolonged use, and increased intraocular pressure and glaucoma can occur, requiring regular monitoring 13, 14
Mood disturbances ranging from euphoria to severe depression and psychosis can occur 13

Risk Factors for Complications

Doses exceeding 10 mg daily for more than 18 months significantly increase risk of severe complications 13
Pre-existing conditions like diabetes, hypertension, and osteoporosis increase risk 15

Monitoring Recommendations

Baseline and annual bone mineral density testing for patients on long-term therapy, and regular assessment for vertebral compression fractures 13, 16
Regular eye examinations for cataracts and glaucoma, with more frequent monitoring for patients with pre-existing eye conditions 14, 16

Special Considerations

Children on long-term therapy are at risk for growth suppression 16

Long-Term Effects of Prednisone

Introduction to Prednisone Therapy

Prolonged prednisone therapy, especially at doses >10 mg daily, is frequently associated with well-known drug toxicities and should be avoided, with treatment courses ideally limited to 6-8 weeks unless absolutely necessary, as recommended by the American Association for the Study of Liver Diseases 17

Cardiovascular Effects

The American College of Cardiology suggests that observational studies indicate long-term use of higher doses (≥5 mg prednisone) in rheumatoid arthritis patients is associated with higher cardiovascular event risk 18

Metabolic and Endocrine Effects

The American Association for the Study of Liver Diseases notes that cosmetic changes, including facial rounding, hirsutism, alopecia, dorsal hump, and striae, occur in patients on prolonged prednisone therapy 17
Glucose intolerance/diabetes develops commonly in patients on prolonged prednisone therapy, requiring blood glucose monitoring, as reported by the American Association for the Study of Liver Diseases 17

Ophthalmologic Complications

The American Academy of Ophthalmology recommends regular eye examinations for patients on long-term prednisone therapy, as posterior subcapsular cataracts and increased intraocular pressure can occur 17

Pregnancy

The European League Against Rheumatism states that prednisone and prednisolone can be used in pregnancy but require careful dose management, with daily doses ≤5 mg associated with low risk 19
The European League Against Rheumatism notes that adverse effects during pregnancy at higher doses may include pregnancy-associated osteoporosis, gestational diabetes, serious maternal infections, and preterm birth 19

Special Population Considerations

The American Association for the Study of Liver Diseases recommends that in children with autoimmune hepatitis, the goals of therapy are to eventually be glucocorticoid-free and to prevent the multiple long-term complications of glucocorticoids 17

Steroid-Sparing Approaches

The European Association for the Study of the Liver suggests that for autoimmune hepatitis, prednisone may be discontinued completely after achieving remission, leaving the patient on only azathioprine or alternative glucocorticoid-sparing drugs 17
The European Association for the Study of the Liver recommends considering steroid-sparing agents, such as azathioprine, 6-mercaptopurine, mycophenolate mofetil, cyclosporine A, tacrolimus, or periodic rituximab, when long-term therapy is anticipated 20

Oral Steroid Prescription for Systemic Rash

Introduction to Oral Steroid Use

The American Academy of Dermatology recommends using oral corticosteroids cautiously and only for short courses (typically 1-2 weeks) in systemic rashes, as they carry significant risks including rebound flaring, metabolic complications, and should never be considered for maintenance therapy 21
The American Academy of Dermatology suggests using oral steroids only as a bridge therapy while initiating steroid-sparing treatments, not as standalone or chronic therapy 21

When to Use Oral Steroids

Oral steroids are appropriate for acute, severe, rapidly progressive rashes that are steroid-responsive 21
The British Medical Journal recommends considering oral steroids for short-term control (1-2 weeks maximum) while optimizing other systemic or topical therapies, but avoiding their use in chronic dermatoses unless absolutely necessary 22, 21

Dosing Strategy

For severe widespread involvement, the British Journal of Dermatology recommends a dose of 0.75-1.0 mg/kg daily 23, 24
For moderate disease, the British Journal of Dermatology suggests a dose of 0.5 mg/kg daily 23, 24
The maximum daily dose is typically 60-80 mg, according to the British Journal of Dermatology and the Journal of Crohn's and Colitis 23, 25

Alternative Approaches to Consider First

The British Medical Journal and the American Academy of Dermatology recommend optimizing topical therapy and considering steroid-sparing alternatives before prescribing oral steroids 22, 21
High-potency topical corticosteroids (e.g., clobetasol propionate) can be as effective as oral steroids for many conditions with fewer systemic effects, according to the British Journal of Dermatology 23, 26

Major Pitfalls to Avoid

The American Academy of Dermatology warns that the most significant risk of oral steroid use is severe rebound flaring upon discontinuation, which can be worse than the original presentation 21
The British Medical Journal and the American Academy of Dermatology advise against using systemic steroids for more than 2 weeks without compelling justification, and never for maintenance therapy 22, 21

Documentation Requirements

The American Academy of Dermatology recommends documenting clear justification for steroid use, expected duration, and plan for transition to steroid-sparing therapy 21

Immunosuppressive Effects of Prednisone

Dose-Dependent Immunosuppression

The European League Against Rheumatism recommends that concomitant low-dose corticosteroids (mean 6.2 mg/day) do not adversely affect pneumococcal vaccine responses, with 57% of pneumococcal vaccine non-responders taking prednisone >20 mg/day compared with 22% of responders 27
High-dose glucocorticoids (>20 mg/day) adversely impact pneumococcal vaccine responses, according to the American College of Rheumatology 27

Vaccine Response Impairment

Low-dose glucocorticoids (<10 mg/day) taken concomitantly with other therapy have not been found to impact pneumococcal vaccine responses, as stated by the European Respiratory Society 27

Prednisone Dose‑ and Duration‑Dependent Adverse Effects and Monitoring Guidelines

Risk of Dose‑ and Duration‑Related Adverse Effects

Prednisone produces significant dose‑ and duration‑dependent adverse effects; limiting courses to ≤ 6 weeks whenever possible reduces the risk of serious complications, and therapy > 6 weeks markedly increases that risk. American Society of Hematology recommendation. 28
Hyperglycemia and worsening of diabetes can develop rapidly, especially at doses > 20 mg/day, necessitating blood‑glucose monitoring even during short courses. 28
Hypertension may appear or worsen quickly; regular blood‑pressure checks are required. 28
Gastric irritation and an increased risk of peptic ulcer disease occur, particularly when prednisone is combined with NSAIDs. 28

Short‑Term Serious Complications (≤ 6 weeks)

Avascular necrosis of bone can occur even with short‑term prednisone use, although it is uncommon. 29
Fatal varicella‑zoster infections have been reported in immunocompetent individuals receiving short‑term systemic corticosteroids. 29

Long‑Term Organ‑Specific Risks (≥ 6 weeks)

Posterior subcapsular cataracts develop with prolonged prednisone therapy. 28

Baseline Assessment Prior to Initiating Prednisone

Evaluate comorbid conditions that heighten risk (e.g., hypertension, diabetes, cardiovascular disease, osteoporosis, peptic ulcer disease, glaucoma, chronic infections). American Society of Hematology guidance. 30
Record baseline measurements of blood pressure, blood glucose, body weight, and bone mineral density when long‑term therapy is anticipated. 28

Ongoing Monitoring During Therapy

Blood pressure and blood glucose should be monitored regularly, even during short courses of prednisone. 28
Conduct mental‑health assessments for depression, fatigue, and mood disturbances while patients receive corticosteroids. 28
Sleep disturbances are common and significantly impair quality of life; clinicians should inquire about insomnia and related symptoms. 28

Risk‑Minimization Strategies

American Society of Hematology strongly recommends limiting prednisone courses to ≤ 6 weeks to avoid the heightened risk of side effects associated with longer exposure. 28
Underestimation of neuropsychiatric effects is a frequent pitfall; mood disturbances and sleep disruptions affect > 50 % of patients receiving prednisone. 28
Failure to limit therapy duration beyond 6 weeks substantially raises adverse‑event risk without providing additional therapeutic benefit for most indications. 28
Inadequate monitoring—particularly omission of blood‑pressure and glucose checks—poses a safety concern even for short‑term regimens. 28

High‑Risk Populations

Female patients have a higher susceptibility to glucocorticoid‑related adverse events. Annals of the Rheumatic Diseases analysis. 30

All facts are derived from cited peer‑reviewed sources and presented in English with generic patient descriptors for guideline use.

Guideline Recommendations for Prolonged Systemic Glucocorticoid Therapy (> 14 Days)

1. Indications for Supplementation and Peri‑operative Management

Calcium and vitamin D supplementation should be initiated when daily prednisone (or equivalent) exceeds 7.5 mg for more than 3 months to mitigate osteoporosis risk. 31
Patients receiving glucocorticoids for longer than 1 month require peri‑operative glucocorticoid stress‑dose coverage for any surgical procedure because of the risk of adrenal insufficiency. 31

2. Baseline and Ongoing Monitoring Requirements

Baseline comorbidity assessment – document existing hypertension, diabetes, cardiovascular disease, osteoporosis, peptic ulcer disease, glaucoma, and chronic infections before starting prolonged therapy. 31
Routine clinical surveillance – monitor body weight, peripheral edema, and signs of cardiac insufficiency at regular intervals. 31
Laboratory and ocular monitoring – check serum lipid profile and intra‑ocular pressure periodically, tailoring frequency to individual dose and duration. 31

3. Dose Minimization and Tapering Strategies

Maintain the lowest effective glucocorticoid dose and attempt tapering once disease activity permits. 31
Re‑evaluate the indication for continued glucocorticoid use at each clinical encounter. 31
Aim for a maintenance dose of ≤ 5 mg prednisone (or equivalent) daily whenever feasible, as doses ≤ 5 mg are associated with a low risk of serious adverse events. 32

4. Prophylactic Interventions for High‑Risk Patients

Initiate bisphosphonate therapy in patients with additional risk factors for bone loss, guided by bone‑mineral‑density assessment. 31
Provide gastro‑protective agents (proton‑pump inhibitor or misoprostol) when glucocorticoids are combined with non‑steroidal anti‑inflammatory drugs. 31

5. Steroid‑Sparing Therapeutic Alternatives

For chronic inflammatory conditions, prioritize biologic disease‑modifying antirheumatic drugs (DMARDs) or conventional synthetic DMARDs over long‑term glucocorticoid therapy. 33

6. Pediatric Considerations

Recognize that children on prolonged systemic glucocorticoids are susceptible to growth suppression; adjust treatment plans accordingly. [31][33]

7. Patient Education and Documentation

Discuss potential adverse effects with patients before initiating glucocorticoid therapy. 31
Reinforce key management points (dose, taper schedule, side‑effect monitoring) during follow‑up visits. 31
Issue a “glucocorticoid card” for patients on extended courses, recording the start date, initial dose, and subsequent dose reductions. 31